Tvardi Therapeutics initiates REVERTIPF trial in idiopathic pulmonary fibrosis
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has reached a significant milestone by dosing the first patients in its REVERTIPF trial. The 12-week, randomized, double-blind study is designed to assess the safety and clinical efficacy of TTI-101. This novel STAT3 inhibitor is being tested at three distinct doses, […]